Form 4: Boston Scientific Executive Exercises Options and Sells Shares Under 10b5-1 Plan

A Boston Scientific executive, Arthur C. Butcher, exercised stock options and sold shares under a pre-established 10b5-1 trading plan.

Summary

• Arthur C. Butcher, an Executive Vice President at Boston Scientific, executed transactions involving the company's stock on November 25, 2024.
• These transactions included the exercise of stock options to acquire 3,177 shares at $22.71 and 1,009 shares at $17.26.
• Following the option exercises, Mr. Butcher sold 14,010 shares at a weighted average price of $89.2694.
• The transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on November 22, 2023.
• Mr. Butcher also holds 13,373 shares indirectly through the company's 401(k) plan.

Sentiment

Score: 5

Explanation: The document reflects routine executive transactions under a pre-arranged plan, which is neither positive nor negative.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, although this was done under a pre-arranged plan.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are often part of their compensation packages. The use of 10b5-1 plans is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including competitors like Medtronic (MDT) and Abbott Laboratories (ABT).
• The vesting schedules for stock options, such as the four-year vesting mentioned, are typical in the industry.
• The sale of shares after exercising options is a standard way for executives to realize the value of their equity compensation.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they are part of a pre-arranged plan and do not indicate a change in the company's fundamentals.

Key Dates

Keywords

stock options, insider trading, 10b5-1 plan, executive compensation, share sale, Boston Scientific, BSX